A new breast cancer genomic test could spare millions of women from the ordeal of chemotherapy, according to the results of a landmark trial that may reshape healthcare guidelines around the globe. The findings point toward a future in which treatment is tailored far more precisely to each patient, sparing many the harsh toll of a therapy they may not actually need.

The Problem With Current Treatment

Breast cancer is the world’s most prevalent form of the disease, and its treatment typically begins with surgery to remove tumours. From there, chemotherapy is often recommended whenever doctors believe there is a meaningful risk the cancer might return.

The trouble is that chemotherapy comes at a steep cost to patients. Its toxic side-effects can include hair loss, rashes, nausea, insomnia, and fatigue, making the experience physically and emotionally gruelling. For some women, the consequences reach even further, leading to life-altering outcomes such as infertility, cognitive impairment, or early menopause.

For decades, patients faced this difficult reality with little room for choice. The new test aims to change that fundamentally.

A Smarter Way to Decide

Scientists have developed a genomic test capable of identifying who genuinely needs chemotherapy and who does not. This breakthrough allows doctors to determine which patients can safely skip the treatment altogether, opening the door to a new era of personalised medicine.

The implications are significant. By distinguishing between those who will benefit from chemotherapy and those who will not, the test offers a path to avoid unnecessary suffering without raising the risk that the cancer will come back.

These results are being presented at the American Society of Clinical Oncology’s annual meeting in Chicago, the largest cancer conference in the world, underscoring the weight the scientific community is placing on the findings.

Inside the Optima Trial

The evidence comes from the Optima trial, led by University College London. This was a substantial international effort, following more than 4,000 patients with newly diagnosed breast cancer across six countries: the UK, Norway, Sweden, Australia, New Zealand, and Thailand.

The central finding was striking. Patients who scored low on the genomic test could be treated safely with hormone therapy alone, without the addition of chemotherapy.

For one participant, the impact was deeply personal. She told the Guardian that being able to skip chemotherapy felt “like Christmas.” Nine years after her diagnosis, having taken the test and forgone chemotherapy, she remains healthy and is enjoying a full and active life.

Expert Perspectives

Professor Rob Stein, the trial’s chief investigator and a professor of breast oncology at UCL, framed the achievement in terms of a long-standing dilemma in cancer care. He explained that the trial addresses the persistent challenge of identifying who truly benefits from chemotherapy and who does not, with findings showing that many patients can safely avoid it without compromising their outcomes.

He described the results as an important step toward more personalised treatment, noting that the trial successfully used tumour biology to guide decisions rather than relying solely on traditional clinical features. For patients, he said, this means many may be spared the physical and emotional burden of chemotherapy and its potential long-term effects. For health systems, it represents a more efficient and evidence-based use of resources.

How the Test Works

At the heart of this advance is the Prosigna test, developed by the global diagnostics company Veracyte. The test analyses the activity of 50 genes within tumour tissue.

By examining these genes, it determines the molecular subtype of the cancer and generates a score that reveals the risk of the disease returning over the next decade. Armed with this information, doctors can make a far more informed judgment about whether chemotherapy is genuinely worthwhile for a particular patient.

The Study Design and Results

The randomised trial involved 4,429 patients aged 40 or above, all with hormone-positive breast cancer. This is the most common form of the disease, accounting for up to 80% of breast cancer cases worldwide, which makes the findings broadly relevant.

Participants were divided into two groups, each following a different approach:

• In the standard treatment group, patients received chemotherapy followed by hormone therapy.
• In the second group, patients had their tumours analysed using the genomic test. Those with a high score received both chemotherapy and hormone therapy, while those with a low score were treated with hormone therapy alone.

Radiotherapy and other treatments were administered as usual to both groups, keeping the comparison focused squarely on the role of chemotherapy.

The outcomes were remarkably reassuring. Within the second group, results were extremely similar regardless of whether chemotherapy was given. Five years after treatment, 95% of those who received both chemotherapy and hormone therapy were alive and free from recurrence. Among those who skipped chemotherapy, 94% were also alive and recurrence-free.

That narrow one-percentage-point difference carries a powerful message: for patients with low test scores, chemotherapy offered little or no additional benefit. In practical terms, these patients could safely avoid the treatment and its associated side-effects.

A Note on Male Patients

Some men also participated in the study, which received funding from the National Institute for Health and Care Research, Veracyte, and various cancer charities. However, the number of male participants was too small to draw firm conclusions for this group, leaving that as an area for future investigation.

Practice-Changing Evidence

Professor Iain MacPherson, a co-chief investigator and professor of breast oncology at the University of Glasgow, emphasised the strength of the findings. He described the trial as providing robust, practice-changing evidence that chemotherapy use can be safely reduced for many patients with hormone-sensitive breast cancer.

He characterised the results as a major step forward in delivering more personalised and precise care, ensuring that treatment decisions are driven by what will genuinely improve patient outcomes while avoiding unnecessary toxicity. The potential impact, he noted, is substantial for both patients and health services alike.

Why This Matters

The promise of this breast cancer genomic test lies in its ability to resolve a difficult balancing act. For years, the cautious approach has meant that many patients underwent chemotherapy as a precaution, even when it may not have improved their chances. The cost of that caution was measured in side-effects, lost fertility, and diminished quality of life.

By using the biology of the tumour itself to guide decisions, this approach shifts the calculus. It allows medicine to be both safer and more humane, reserving an aggressive treatment for those who will truly benefit while freeing others from an unnecessary burden.

The broader significance extends to healthcare systems as well. Reducing the number of patients who undergo chemotherapy could ease pressure on resources and direct care more efficiently, all while maintaining excellent outcomes.

Looking Ahead

If adopted into clinical guidelines, this test could mark a turning point in how breast cancer is treated worldwide. The vision of personalised medicine, where decisions are tailored to the individual rather than applied broadly, moves closer to reality with results like these.

For the millions of women diagnosed with hormone-positive breast cancer each year, the prospect is genuinely hopeful: the possibility of effective treatment without the gruelling side-effects that have long accompanied it.

As always, this overview is meant to inform rather than to advise. Anyone facing decisions about cancer treatment should discuss their specific situation with a qualified oncologist or healthcare provider, who can offer guidance suited to their individual circumstances.